TrialThe lancet. Diabetes & endocrinology2023

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.

Lori M Laffel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.